Abstract 2320P
Background
Dedifferentiated liposarcomas (DDLS) are malignant soft-tissue tumors that are characterized by focal amplifications on chromosome 12q. They do not respond well to chemotherapy and no approved targeted therapy for DDLS is available. Through whole-exome/genome and RNA sequencing, we found that these structural changes generate open reading frames, leading to potential gene fusions and immunogenic neoepitopes, which modulate immune microenvironment and could serve as therapeutic targets.
Methods
We first analyzed a DDLS cell line (T449). Gene fusions were identified using two variant calling pipelines, Arriba (DKFZ) and EasyFuse (TRON). Fusion-derived (FD) peptides were used as input for HLA binding prediction by NetMHCpan 4.1. For targeted mass spectrometry (MS) analysis, we applied an ultra-sensitive parallel reaction monitoring workflow. For untargeted MS analysis, we combined data-independent acquisition MS with ion mobility separation by high-field asymmetric waveform ion mobility spectrometry. Mass spectra were compared to the human proteome, FD sequences, and libraries of in silico predicted fragment spectra. We used a modified MANAFEST protocol for the expansion of antigen-reactive CD4 and CD8 T cells.
Results
Candidate peptides for the targeted MS approach were selected from overlapping results of both pipelines. For the T449 cell line, we detected 128 fusion events resulting in 493 potential neoepitopes. We selected 46 peptides for targeted MS analysis and identified eight distinct FD neoepitopes. Analysis by untargeted MS yielded 15,578 peptide sequences, including five FD neoepitope candidates. We analyzed tumors from DDLS patients by targeted and untargeted MS analysis as well as their peripheral T-cell repertoire from expansion cultures. In a retrospective analysis of 67 patients, we observed a correlation between the quantity of fusions and specific tumor-infiltrating immune cell fractions.
Conclusions
We show results of our pipeline for the detection of FD neoepitopes using both targeted and untargeted MS approaches and explore the presence of neoepitope-specific T cells in the peripheral blood of DDLS patients. We believe that our work will lead to the clinical development of personalized treatment options for DDLS patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Helmholtz Institute for Translational Oncology Mainz.
Disclosure
P. Horak: Financial Interests, Personal, Speaker’s Bureau: Roche, Trillium GmbH; Financial Interests, Personal, Speaker, Consultant, Advisor: Platomics GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2256P - The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study
Presenter: Yeonghak Bang
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2258P - Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Presenter: Lidwien Smabers
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08